Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 2/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | F3 | P13726 | 2/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | NQO2 | P16083 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6266537 | 1.00 | KDM4E (0.53) | KDM4ELMNACYP3A4TP53TSHR | |
| SCHEMBL9148376 | 0.87 | LTB4R (0.49) | KDM4ELMNACYP3A4TP53TSHR | |
| SCHEMBL8416685 | 0.87 | LTB4R (0.49) | KDM4ELMNACYP3A4TP53TSHR | |
| SCHEMBL1278753 | 0.84 | KDM4E (0.57) | KDM4ELMNACYP3A4TP53TSHR | |
| SCHEMBL1278751 | 0.84 | KDM4E (0.57) | KDM4ELMNACYP3A4TP53TSHR | |
| SCHEMBL13181157 | 0.82 | KDM4E (0.55) | KDM4ELMNACYP3A4TP53TSHR | |
| SCHEMBL12479217 | 0.82 | KDM4E (0.55) | KDM4ELMNACYP3A4TP53TSHR | |
| SCHEMBL30472942 | 0.81 | KDM4E (0.53) | KDM4ELMNACYP3A4TP53TSHR | |
| SCHEMBL4747206 | 0.81 | KDM4E (0.53) | KDM4ELMNACYP3A4TP53TSHR | |
| SCHEMBL16877138 | 0.80 | ALDH1A1 (0.54) | KDM4ELMNACYP3A4TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007100182-A1 | POLYMER NANOCAPSULES AND THE PROCESS FOR PREPARING THE SAME, AND THE SKIN EXTERNAL COMPOSITION CONTAINING THE NANOCAPSULES | AMOREPACIFIC CORPORATION (KR) | 2007-09-07 | — | — | WO | claimed |
| CN-120136763-A | C-3 benzylated indole compound, preparation method and application thereof | 遵义医科大学 | 2025-06-13 | — | — | CN | disclosed |
| EP-3212184-A1 | SUBSTITUTED TETRAHYDROPYRANS AND METHOD OF USE | Abbvie S.a.r.l. (LU) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016069891-A1 | SUBSTITUTED TETRAHYDROPYRANS AND METHOD OF USE | ABBVIE INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| EP-2137169-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008110583-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-09-18 | — | — | WO | disclosed |
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| WO-2005051904-A2 | NOVEL PROCESSES FOR THE SYNTHESIS OF CYCLOPROPYL COMPOUNDS | PHARMACIA CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | KDM4E 2902/4885LMNA 3139/4885CYP3A4 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.